Sharemaestro Newsreel

TherapeuticsMD, Inc. (29TA.SG) Stock Price, News, Quote & History

The article provides a snapshot of TherapeuticsMD, Inc. (29TA.SG) stock performance as of August 7, 2026. It highlights the stock's price, recent news, and historical data. Key performance metrics like Year-To-Date and 1-Year trailing total returns are compared against the S&P 500 index.

Supernus and Indivior Combine to Build $2.2B CNS Biopharmaceutical Company

Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock deal to form a $2.2 billion central nervous system (CNS) biopharmaceutical company. The combined entity, operating as Supernus, Inc., will integrate Indivior's opioid use disorder franchise, centered on SUBLOCADE, with Supernus's diverse neurology and …

Dr. Reddy’s Laboratories (NYSE: RDY) secures FDA approval for rituximab biosimilar

Dr. Reddy's Laboratories (NYSE: RDY) has received U.S. FDA approval for its rituximab biosimilar, a drug highly similar to Rituxan, intended for the U.S. market. This approval follows a successful Pre-License Inspection at their Hyderabad facility and marks a significant expansion of their global …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating Aquestive Therapeutics, Inc. (NASDAQ:AQST) for potential corporate wrongdoing. The firm encourages stockholders who purchased Aquestive securities before June 16, 2025, and still hold them, to contact them to assist in the investigation. The firm operates on a …

BioXcel Therapeutics Wins Deferral on $9.0M Payment, Liquidity Covenant Cut to $6.25M Under Oaktree Deal

BioXcel Therapeutics (BTAI) has secured a deferral on a $9.0 million principal and interest payment with Oaktree until August 31, 2026, via the Eleventh Amendment to its Credit Agreement. This amendment also reduces the minimum liquidity covenant to $6.25 million. By August 10, 2026, …

Supernus Pharmaceuticals Reports 32% Second-Quarter 2026 Revenue Growth, Raises Full-Year Guidance and Announces Merger with Indivior

Supernus Announces Second Quarter 2026 Financial Results

Supernus Pharmaceuticals, Inc. Total revenues were $219.1 million in the second quarter 2026, a 32% increase compared to same period last year. Combined revenues of the Company's four growth products increased to $175.7 million in the second quarter 2026, representing an increase of 52% …

Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

Indivior Pharmaceuticals reported strong second-quarter 2026 financial results, with total net revenue up 14% year-over-year to $343 million and SUBLOCADE net revenue increasing by 21% to $253 million. The company has raised its full-year 2026 guidance, now expecting total SUBLOCADE net revenue growth of …

116,100 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Bought by Militia Capital Management LLC

Militia Capital Management LLC recently acquired 116,100 shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the first quarter, valued at approximately $3.5 million. This purchase is part of broader institutional investment activity, with hedge funds and other institutional investors collectively owning 54.05% of the …

Elanco Animal Health Incorporated $ELAN Shares Bought by Defilade Capital Management L.P.

Defilade Capital Management L.P. significantly increased its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 132.0% in the first quarter, now owning over 931,000 shares valued at $22.28 million. Other institutional investors also adjusted their positions, and insider activity shows CEO Jeffrey N. Simmons …

Curium strikes up to $8 billion deal for radiopharma peer Lantheus

Curium has agreed to acquire radiopharmaceutical company Lantheus Holdings in a deal valued at up to $8 billion. Lantheus shareholders will receive $102.50 per share in cash, with potential additional payments of up to $12 per share based on sales targets, representing a 14.9% …

Arrowstreet Capital Limited Partnership Has $6.37 Million Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH

Arrowstreet Capital Limited Partnership reduced its stake in Amphastar Pharmaceuticals by 41.9% in Q1 2026, holding 325,291 shares valued at $6.37 million. Despite this, institutional ownership remains high at 65.09%, with other firms like Dimensional Fund Advisors and State Street increasing their positions. The …

Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Amundi

Amundi reduced its stake in Teva Pharmaceutical Industries Ltd. by 45.3% in the first quarter, selling over 1.46 million shares but still holding 1.77 million shares. Despite this, institutional ownership remains strong, with several major investors increasing their positions. Analysts maintain a "Moderate Buy" …

Aurora Cannabis (NASDAQ:ACB) in Focus as Cannabis Sentiment Shifts

Aurora Cannabis (NASDAQ:ACB) is gaining attention as the cannabis sector experiences a shift in sentiment, driven by evolving regulatory discussions and a strong focus on medical applications. The company is highlighted for its established presence in the medical cannabis segment across various international markets. …

Supernus and Indivior Agree to All-Stock Merger of Equals

Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. announced a definitive agreement to merge in an all-stock, tax-free transaction, creating a U.S. biopharmaceutical company focused on central nervous system (CNS) diseases. The combined entity will be headquartered in Rockville, Maryland, with Supernus CEO Jack A. …

Arrowstreet Capital Limited Partnership Trims Stake in Amneal Pharmaceuticals, Inc. $AMRX

Janus Henderson Group PLC Acquires 1,685,063 Shares of BioAge Labs, Inc. $BIOA

Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Down 4.6% - Time to Sell?

BioAge Labs (NASDAQ:BIOA) Given Buy Rating at BTIG Research

Supernus Pharmaceuticals (NASDAQ:SUPN) Issues Earnings Results, Misses Estimates By $1.43 EPS

This article provides an overview of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), including its current stock price, historical performance, analyst forecasts, and financial data. It highlights key metrics such as market capitalization, earnings per share, revenue, and EBITDA, while also offering insights into the company's …

Why Supernus Pharmaceuticals Stock Topped the Market Today

Key Points The two companies will carry the Supernus name. Supernus also published its latest quarterly earnings release.10 stocks we like better than Supernus Pharmaceuticals › Supernus Pharmaceuticals (NASDAQ: SUPN) began the stock trading week on a high note, announcing a major merger alongside …

Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Q2 CY2026 Sales, Stock Jumps 24.9%

Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Q2 CY2026 Sales, Stock Jumps 24.9% Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 32.4% year on year to $219.1 million. The company's full-year revenue guidance of $875 …

Amylyx will discuss second-quarter results in Aug. 6 webcast

Indivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat Estimates

Research Analysts Set Expectations for Alkermes Q3 Earnings

Organogenesis Holdings, Inc. Class A Revenue Breakdown – LSX:A2PA31

Organogenesis Holdings, Inc. Class A (LSX:A2PA31) generated 479.37 million EUR in revenue last year. The Advanced Wound Care segment was the top-performing segment, contributing 452.31 million EUR, an increase from 438.21 million EUR the prior year. The United States was the primary geographic contributor, …

Sei Investments Co. Grows Stock Position in Haleon PLC Sponsored ADR $HLN

Sei Investments Co. significantly increased its stake in Haleon PLC Sponsored ADR (NYSE:HLN) by 89.4% in the first quarter, now owning 1.29 million shares valued at $12.87 million. Other institutional investors also adjusted their holdings, contributing to hedge funds and institutional investors owning 6.67% …

Earnings call transcript: HUTCHMED posts solid H1 2026 growth, stock edges up

HUTCHMED reported strong H1 2026 results, with total revenue reaching $278 million and oncology sales up 23% to $162 million, driven by demand for its cancer drugs. The company maintained profitability despite increased R&D spending and ended the period with $1.4 billion in cash. …

Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock, tax-free transaction to create a leading diversified central nervous system (CNS) biopharmaceutical company. The combined entity, to be named Supernus, Inc., is expected to have approximately $2.2 billion in annual revenues and generate $125 …

Dr. Reddy's Laboratories rises Monday, outperforms competitors

Dr. Reddy's Laboratories Ltd. shares increased by 1.94% on Monday, closing at 1,169.90 Indian rupees. This performance outperformed the overall market, as the BSE SENSEX Index rose by 0.70%. The company's stock closed 17.29% below its 52-week high.

Is Neurocrine Biosciences (NBIX) A Bargain After Strong Q2 Results And Higher Guidance?

Neurocrine Biosciences (NBIX) reported strong Q2 2026 results and raised full-year INGREZZA sales guidance, yet its share price declined by about 10% on the day of the announcement, despite positive longer-term momentum. The stock is currently valued at $166.80, considered 13.5% undervalued by Simply …

Precision Trading with United Therapeutics Corporation (UTHR) Risk Zones

This article provides a precision trading analysis for United Therapeutics Corporation (UTHR), indicating divergent sentiment across various time horizons and suggesting choppy conditions. It highlights a breakdown in progress with elevated downside risk and offers three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along …

KPMG agrees to settle its part of Canopy Growth securities case

KPMG has agreed to a settlement in a securities class action related to its audit of Canopy Growth Corporation. The settlement specifically addresses whether KPMG's auditor's report for the fiscal year ended March 31, 2022, contained a misrepresentation. This agreement applies only for settlement …

ETFs Investing in Cronos Group Inc Stocks

This article lists several ETFs that hold Cronos Group Inc (7CI) stocks, providing details such as market value, weight, issuer, management style, focus, expense ratio, and AUM for each fund. The ETFs mentioned include the ETFMG Alternative Harvest ETF (MJ), Global X Marijuana Life …

Amneal Pharma A earnings beat by $0.07, revenue topped estimates

Amneal Pharma A (NASDAQ: AMRX) reported strong second-quarter results, surpassing analyst estimates with EPS of $0.300 and revenue of $796.2 million. The company also provided optimistic full-year 2026 guidance, expecting EPS between $0.960-$1.060 and revenue between $3.100B-$3.200B. AMRX stock has shown significant growth, increasing …

Form 4 Indivior PLC For: 3 August By Investing.com

This article announces the filing of Form 4 for Indivior PLC on August 3rd. It appears to be a very brief notification from Investing.com, typical of automated financial news updates regarding regulatory filings. The content primarily consists of navigation, advertisements, and market data rather …